These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings

Core Viewpoint - Haemonetics Corporation reported strong earnings for Q3, exceeding analyst expectations in both earnings per share and sales figures, despite a subsequent decline in share price [1]. Financial Performance - The company reported quarterly earnings of $1.31 per share, surpassing the analyst consensus estimate of $1.25 per share [1]. - Quarterly sales reached $338.967 million, exceeding the analyst consensus estimate of $331.616 million [1]. - Haemonetics raised its FY2026 adjusted EPS guidance from a range of $4.80-$5.00 to $4.90-$5.00 [1]. Stock Performance - Following the earnings announcement, Haemonetics shares fell by 6%, trading at $61.13 [1]. Analyst Ratings and Price Targets - Barrington Research analyst Michael Petusky maintained an Outperform rating on Haemonetics and raised the price target from $93 to $94 [3]. - Mizuho analyst Anthony Petrone also maintained an Outperform rating but lowered the price target from $90 to $80 [3].